Sponsor: Novartis Therapeutics

Overview: CAD-1883 is a small molecule and modulator of calcium-activated potassium ion channels. It is hypothesized to improve symptoms in patients with spinocerebellar ataxia through regulating neuronal firing of cells in the cerebellum.

Ataxia Types Included in Clinical Trials (planned):

SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA17, ARCA1

Potential Utility in Other Ataxias (i.e. sporadic, unknown cause, other SCAs, etc,)

Yes

Current Stage of Development: A Phase 2 clinical trial sponsored by Cadent Therapeutics was planned to begin in 2022 and would have included participants with SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA17, and ARCA1. However, the clinical trial was withdrawn in January 2021 following the acquisition of Cadent Therapeutics by Novartis Therapeutics. According to clinicaltrials.gov, “as part of a pipeline assessment, the Synchrony-1 trial will not proceed as initially scheduled.  

Clinicaltrials.gov Reference – https://clinicaltrials.gov/ct2/show/NCT04301284

A Phase 2 clinical trial sponsored by Cadent Therapeutics of CAD-1883 in individuals with essential tremor was completed in 2019. No serious adverse events were observed in treated patients in this study.

Clinicaltrials.gov Reference – https://www.clinicaltrials.gov/ct2/show/results/NCT03688685

News/Press Releases:

December 17, 2020 – Novartis announced that the company has entered an agreement to acquire Cadent Therapeutics. The acquisition included the CAD-1883 clinical stage program for movement disorders.

June 4, 2019 – FDA granted Orphan Drug designation to CAD-1883 (Cadent Therapeutics), an investigational treatment for spinocerebellar ataxia.